Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan.
Department of Quality and Safety Management, Osaka Metropolitan University Hospital, Osaka, Japan.
Int J Clin Oncol. 2024 Dec;29(12):1840-1849. doi: 10.1007/s10147-024-02622-z. Epub 2024 Sep 15.
Immune checkpoint inhibitors (ICIs) have been approved as first-line therapy for advanced non-small cell lung cancer (NSCLC). The probiotic MIYAIRI 588 can potentially improve the outcomes of patients with advanced NSCLC treated with ICI. However, the impact of other probiotics on ICI-treatment efficacy remains unclear. Thus, we aimed to clarify the association between BIO-three use and treatment outcomes in patients with advanced NSCLC treated with ICI.
This retrospective study included patients aged ≥ 18 years with advanced or recurrent NSCLC who had received ICI monotherapy or ICI plus chemotherapy. Concomitant therapy with probiotic bacteria was defined as receiving it within 180 days before ICI therapy.
Here, 289 patients were enrolled, including 23 (8.0%) receiving BIO-three. In the multivariable analysis, the progression-free survival (PFS) and overall survival (OS) of patients receiving BIO-three tended to be longer than those of patients not receiving probiotic therapy (PFS, hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.43-1.30; p = 0.33; OS, HR 0.69; 95% CI 0.37-1.28; p = 0.24). After propensity score matching with weighted adjustment, patients receiving BIO-three tended to have prolonged PFS (median PFS [range] 7.6 months [2.6-17.4] vs 3.2 months [1.6-7.0]; HR 0.53; 95% CI 0.25-1.12; p = 0.09) and OS (median OS [range] 25.6 months [10.8-not reached] vs 10.9 months [7.3-not reached]; HR 0.57; 95% CI 0.24-1.36; p = 0.20) than those not receiving probiotic therapy.
This study suggests the prognostic impact of concomitant BIO-three use in patients with advanced NSCLC on ICI treatment.
免疫检查点抑制剂（ICI）已被批准作为晚期非小细胞肺癌（NSCLC）的一线治疗药物。益生菌 MIYAIRI 588 有可能改善接受 ICI 治疗的晚期 NSCLC 患者的结局。然而，其他益生菌对 ICI 治疗效果的影响尚不清楚。因此，我们旨在阐明接受 ICI 治疗的晚期 NSCLC 患者中 BIO-three 使用与治疗结局之间的关系。
这是一项回顾性研究，纳入了年龄≥18 岁的接受 ICI 单药或 ICI 联合化疗治疗的晚期或复发性 NSCLC 患者。在 ICI 治疗前 180 天内接受益生菌细菌联合治疗定义为同时治疗。
本研究共纳入 289 例患者，其中 23 例（8.0%）接受 BIO-three 治疗。多变量分析显示，接受 BIO-three 治疗的患者的无进展生存期（PFS）和总生存期（OS）长于未接受益生菌治疗的患者（PFS，风险比[HR]0.75；95%置信区间[CI]0.43-1.30；p=0.33；OS，HR 0.69；95% CI 0.37-1.28；p=0.24）。经过加权调整的倾向评分匹配后，接受 BIO-three 治疗的患者的 PFS 有延长趋势（中位 PFS[范围]7.6 个月[2.6-17.4]比 3.2 个月[1.6-7.0]；HR 0.53；95% CI 0.25-1.12；p=0.09）和 OS 有延长趋势（中位 OS[范围]25.6 个月[10.8-未达到]比 10.9 个月[7.3-未达到]；HR 0.57；95% CI 0.24-1.36；p=0.20），长于未接受益生菌治疗的患者。
本研究提示接受 BIO-three 治疗可能对接受 ICI 治疗的晚期 NSCLC 患者的预后有影响。
